Categories: PR Newswire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

NEW YORK, May 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  



The investigation concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On April 10, 2024, the U.S. Department of Justice (“DOJ”) issued a press release announcing that it had filed a complaint against Regeneron under the False Claims Act. The lawsuit accuses the Company of failing to report millions of dollars in discounts provided to drug distributors. As a result, the DOJ alleges that the average selling price of Regeneron’s Eylea drug was inflated above the amount allowed by Medicare. 

On this news, Regeneron’s stock price fell $31.50 per share, or approximately 3.36%, over two trading sessions, to close at $904.70 on April 12, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.  

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-regeneron-pharmaceuticals-inc—regn-302153300.html

SOURCE Pomerantz LLP

Dayang Norazhar

Recent Posts

Hisense Enhances UEFA EURO 2024™ Excitement with Immersive Fan Zones

QINGDAO, China, June 23, 2024 /PRNewswire/ -- Hisense, a global home appliance and consumer electronics…

2 hours ago

Malaysia Airlines partners with Huawei to boost outbound travel market in China

KUALA LUMPUR -- Malaysia Airlines has forged a strategic partnership with Chinese tech giant Huawei to…

4 hours ago

Sg Bakap by-election: No early voting centre to open on July 2

NIBONG TEBAL -- No early voting centre will be opened on early voting day for the…

5 hours ago

PM Anwar: Govt committed to reducing carbon footprint, promoting sustainable practices

KUALA LUMPUR -- The MADANI government is committed to reducing the country’s carbon footprint and promoting…

5 hours ago

Loke: Driving institutes involved in corruption face licence cancellation

SEREMBAN -- Driving institutes (IM) have been warned not to be involved in illegal 'kopi O'…

5 hours ago

Portugal cruise into Euro 2024 knockout stages, Belgium bounce back

DORTMUND – Portugal outclassed Turkey to secure their place in the last 16 of Euro…

5 hours ago